Genomed Spólka Akcyjna provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification and Sanger sequencing of DNA regions, the comparison of the sequences, and the interpretation of the results by diagnosticians. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis and the sequencing of phage genetic material, or bacteria and yeast genomes; and next-generation sequencing and genetic counseling services. Further, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through the e-shop. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. Genomed Spólka Akcyjna was founded in 2007 and is headquartered in Warsaw, Poland.
Metrics to compare | GENM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENMPeersSector | |
---|---|---|---|---|
P/E Ratio | 15.5x | −6.4x | −0.6x | |
PEG Ratio | - | 0.02 | 0.00 | |
Price/Book | 3.1x | 2.1x | 2.6x | |
Price / LTM Sales | 1.4x | 13.1x | 3.3x | |
Upside (Analyst Target) | - | 48.5% | 39.1% | |
Fair Value Upside | Unlock | −1.8% | 4.5% | Unlock |